X

Trial Profile

A second pivotal trial of piclidenoson for the treatment of rheumatoid arthritis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Piclidenoson (Primary)
Indications Rheumatoid arthritis
Focus Registrational; Therapeutic Use
Acronyms ACROBAT

Most Recent Events

07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is expected to initiate in 2017.
07 Aug 2017 According to a Can-Fite BioPharma media release, based on the favorable safety data from cardiodynamic trial CTP#700287672 company is cleared to initiate this study.
07 Nov 2016 According to a Can-Fite BioPharma media release, protocol has recently been agreed with EMA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com